|
May 1
|
Corcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024
|
|
May 1
|
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
|
|
Apr 29
|
Corcept Completes Enrollment in Phase 4 CATALYST Trial
|
|
Apr 24
|
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
|
|
Apr 23
|
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
|
|
Apr 22
|
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
|
|
Apr 17
|
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
|
|
Apr 16
|
Corcept (CORT) Completes Enrollment in Phase II ALS Study
|
|
Apr 15
|
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
|
Apr 9
|
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
|
|
Apr 8
|
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
|
|
Apr 1
|
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
|
|
Mar 29
|
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
|
|
Mar 29
|
Investing in Corcept Therapeutics (NASDAQ:CORT) five years ago would have delivered you a 114% gain
|
|
Mar 27
|
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
|
|
Mar 25
|
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
|
|
Mar 22
|
Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report?
|
|
Jan 29
|
Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?
|
|
Jan 29
|
Corcept Appoints Roberto Vieira as President, Oncology
|
|
Jan 9
|
Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024
|